Please login to the form below

Not currently logged in
Email:
Password:

AZ appoints Pam Cheng as executive VP, operations and IT

She joins from MSD China where she was president

edit-AZ-Pam-ChengAstraZeneca has named Pam Cheng as executive vice president, operations and IT.

Cheng succeeds David Smith, who is retiring after nearly ten years at the firm. She will be responsible for manufacturing operations and supply chain, procurement and information technology globally.

In the role, she will oversee AZ's progression in driving efficiency and delivering excellence within her field.

Pascal Soriot, CEO at AZ, commented: “I am delighted to welcome Pam to AstraZeneca at a very exciting time for our business. As our pipeline delivers, we will bring an increasing number of new medicines to patients across the globe over the coming years, including important biological therapies as our product mix shifts. 

“Pam will be able to bring to bear her wealth of experience in manufacturing and supply chain management, as well as her experience in emerging markets, particularly China, a key priority for our company.”

Cheng joins from Merck/MSD, where she was most recently chief operating officer and then president of MSD China.

At the company, Cheng gained extensive experience in pharma manufacturing and supply chain management as director of global planning and capacity management and head of global supply chain management and logistics. 

19th June 2015

From: Research, Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics